NutraConnect KEY INGREDIENTS dard group received only the man- sign a written informed consent gosteen extract (STD). form. Exclusion criteria comprised subjects receiving chronic or acute Experimental design treatment for pain or inflammation. Mice were orally supplemented Experimental design with the mangosteen extract at an acute dose of 60 mg/kg (MGS A 5-day, single-blind, randomized and STD groups) or with tap water and drug referencecontrolled cli- as the vehicle (LPS group) thirty nical trialwas conducted. Once minutes before intraperitoneal in- enrolled, subjects were assigned jection of LPS (100 μg/kg). Ninety to one of two groups. For 5 days, minutes after LPS, blood sampling one group (n=12; 6 males and 6 was obtained from the retro-orbital females) received orally 100 mg plexus with animals under ether-in- of nimesulide daily in two equal duced anesthesia. doses, and the other group (n=12; 5 males and 7 females) was sup- TNF-α assay plemented with 600 mg of the mangosteen extract daily in two Concentrations of TNF-α were equal doses. Volunteers reported determined in plasma using an to the research center 2 times du- ELISA kit from R&D Systems, ring the 5-day intervention period: Minneapolis, MN, USA. at baseline (D0) and at the end of the study (D5). Human clinical study Subjects Pain assessment Inclusion criteria incorporated Pain rating according to inten- twenty-four volunteers of both sity of pain perception by the vo- sexes suffering with acute (n=15) lunteers was assessed using a or chronic (n=9) soft tissue condi- visual analogue scale (VAS) at D0 tions; namely, osteoarthritic pain, and D5. Volunteers rated the fol- inflammation of the tendons, and lowing corresponding scores for post-traumatic inflammation. Vo- pain:0 for no pain; 1–3 for mild lunteers were recruited for the pain (incommodious; interfering clinical study after they agreed to little with activities of daily living